Fathi H, et al. - A large-scale systematic review was performed to assess the effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection. Findings based on sustained virological response rates at 12 weeks (SVR12) suggested that for treating genotype 3 (GT3) infections, regimens incorporating newer direct-acting antivirals (DAAs) are more effective than those comprising older DAAs. In addition, ribavirin could be of less benefit in newer DAA regimens than in older DAA regimens for these infections. Evidence from the analysis indicated that DAA regimens can replace Peg-IFN-based regimens for GT3 infection.